A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A

被引：1

作者：

Jimeno, Antonio

Opyrchal, Mateusz

Diamond, Jennifer Robinson

Fountzilas, Christos

Corr, Bradley

Bezi, Ildiko

Wang, Hui

Kwan, Rudolf

Zhi, Jay

Cutler, David

Boland, Patrick McKay

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[3] Athenex, Cranford, NJ USA

[4] Athenex Inc, Buffalo, NY USA

[5] Roswell Pk Canc Inst, Buffalo, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.3032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3032

引用

页数：2